SCHEMBL3534676

SCHEMBL3534676

CCOC(=O)C1CN(C2CCCC2)c2nc(SC)ncc2C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
CDK4 P11802 1/20 0.39
CCND1 P24385 1/20 0.39
CDK6 Q00534 1/20 0.39
ALDH1A1 P00352 9/20 0.38
MAPT P10636 4/20 0.38
HPGD P15428 3/20 0.38
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
POLB P06746 3/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
FOS P01100 1/20 0.35
JUN P05412 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3291780 0.99 MEN1 (0.44) KMT2AMEN1CDK4CCND1CDK6
SCHEMBL10993928 0.87 ALDH1A1 (0.39) KMT2AMEN1CDK4CCND1CDK6
SCHEMBL9956454 0.84 MEN1 (0.47) KMT2AMEN1CDK4CCND1CDK6
SCHEMBL3531188 0.84 KMT2A (0.40) KMT2AMEN1CDK4CCND1CDK6
SCHEMBL11101244 0.83 KMT2A (0.46) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL10994290 0.81 ALDH1A1 (0.41) KMT2AMEN1CDK4CCND1CDK6
SCHEMBL10996263 0.80 CDK4 (0.42) KMT2AMEN1CDK4CCND1CDK6
SCHEMBL3291782 0.79 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL3528616 0.78 SLC6A2 (0.41) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL3290246 0.76 MEN1 (0.40) KMT2AMEN1CDK4CCND1CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642270-B2 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-05 US disclosed
EP-1937681-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP disclosed
WO-2007033232-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR KMT2A 1844/4885MEN1 3337/4885CDK4 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.